Schrodinger, Inc. (SDGR)
| Market Cap | 4.93B |
| Revenue (ttm) | 114.05M |
| Net Income (ttm) | -10.67M |
| Shares Out | 61.34M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $69.88 |
| Previous Close | $70.08 |
| Change ($) | -0.20 |
| Change (%) | -0.29% |
| Day's Open | 70.11 |
| Day's Range | 68.03 - 70.56 |
| Day's Volume | 244,919 |
| 52-Week Range | 46.27 - 117.00 |
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at two investor conferences in July.
I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential ap...
NEW YORK--(BUSINESS WIRE)--Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at two investor conferences in June.
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 100.00% and 10.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Schrodinger (NASDAQ:SDGR) decreased 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.00, which ...
NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger reported financial results for the first quarter of 2021 and provided a company update.
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will participate in the Bank of America Securities 2021 Virtual Healthcare Conference.
vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report first quarter 2021 financial results on May 11, 2021.
NEW YORK--(BUSINESS WIRE)--Schrödinger announced grants made to newly-hired employees pursuant to the company's 2021 Inducement Equity Incentive Plan.
NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger presented new preclinical data from its CDC7 inhibitor program during AACR 21 Annual Virtual Meeting.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that the company will participate in the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.
NEW YORK--(BUSINESS WIRE)--Schrödinger will host a webcast to review the preclinical data being presented at the AACR Annual Meeting.
These three companies have just one thing in common: the potential to offer a long-term windfall for stockholders.
Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor.
NEW YORK--(BUSINESS WIRE)--Schrödinger will participate in the virtual Credit Suisse 2021 Healthcare Innovators Series on March 23, 2021.
This drug discovery company's stock just took a major hit.
NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger announced that preclinical data from its CDC7 program will be presented at the AACR Annual Meeting.
NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger today reported financial results for the fourth quarter and full year 2020.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will provide a corporate overview during the H.C. Wainwright Global Life Sciences Conference.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it has expanded its collaboration with Google Cloud.
Schrodinger is an exciting, next generation drug development and software player. However, at its core, it is a molecular modelling company, leading to vast opportunities. The TAM of the markets in whic...
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its ...
The company announced a partnership with Bristol Myers Squibb.
Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in milestone ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collabor...
Schrödinger stock is almost at half the price since peaking in the summer. Stock dilution hurt investors, but the market is betting on its software growth.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q3 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results fo...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data...
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a conference ...
Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual reality a...
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Schrödinger, Inc. has exhibited a stock price slide since July, even as revenue growth continues above expectations.
Three great performing yet relatively unknown med-tech stocks with a high upside.
Schrödinger's computational platform integrates physics-based methods with machine-learning techniques to enable drug discovery and development of novel materials.
Schrödinger has an innovative computational platform that accelerates the discovery of new molecules for use in therapeutics and industrial materials.
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
About SDGR
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharma... [Read more...]
| Industry Health Information Services | IPO Date Feb 6, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol SDGR |
Financial Performance
In 2020, Schrodinger's revenue was $108.10 million, an increase of 26.36% compared to the previous year's $85.54 million. Losses were -$24.46 million, -0.44% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 89.60, which is an increase of 28.22% from the latest price.